Title:
PHARMACEUTICAL COMPOSITION
Document Type and Number:
WIPO Patent Application WO/2021/106978
Kind Code:
A1
Abstract:
As a novel technology that is useful for cancer vaccine therapy, provided is a pharmaceutical composition that is characterized by being administered in the form of combination of: a Toll-like receptor agonist; LAG-3 protein, a mutant thereof, or a derivative thereof; at least one type of immunogenic substance; and an immune checkpoint inhibitor.
Inventors:
DOI SHUN (JP)
SEGAWA YOSHIHIDE (JP)
TAMADA KOJI (JP)
NAGANO HIROAKI (JP)
HAZAMA SHOICHI (JP)
SEGAWA YOSHIHIDE (JP)
TAMADA KOJI (JP)
NAGANO HIROAKI (JP)
HAZAMA SHOICHI (JP)
Application Number:
PCT/JP2020/043938
Publication Date:
June 03, 2021
Filing Date:
November 26, 2020
Export Citation:
Assignee:
CYTLIMIC INC (JP)
International Classes:
A61K39/00; A61K31/713; A61K38/17; A61K39/39; A61K39/395; A61K45/00; A61K45/06; A61K48/00; A61P35/00; A61P35/02; A61P37/04; A61P43/00; C07K7/06
Domestic Patent References:
| WO2018070069A1 | 2018-04-19 | |||
| WO2018021400A1 | 2018-02-01 | |||
| WO2006121168A1 | 2006-11-16 | |||
| WO2008156712A1 | 2008-12-24 | |||
| WO2010077634A1 | 2010-07-08 | |||
| WO2011066389A1 | 2011-06-03 | |||
| WO2013079174A1 | 2013-06-06 | |||
| WO2001014424A2 | 2001-03-01 | |||
| WO2000037504A2 | 2000-06-29 | |||
| WO2018070069A1 | 2018-04-19 |
Other References:
KANO, Y. ET AL.: "Combined adjuvants of poly(I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion", CANCER SCIENCE, vol. 107, no. 4, 2016, pages 398 - 406, XP055475305, DOI: 10.1111/cas.12861
NAKAJIMA, M. ET AL.: "A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 69, March 2020 (2020-03-01), pages 1651 - 1662, XP037187737, DOI: 10.1007/s00262-020-02518-7
MENON S ET AL., CANCERS, vol. 8, 2016, pages 106
PARDOLL DM., NAT REV CANCER, vol. 12, 2012, pages 252 - 264
WOLCHOK JD., CELL, vol. 162, 2015, pages 937
ONCOIMMUNOLOGY, vol. 1, no. 5, August 2012 (2012-08-01), pages 699 - 716
ONCOIMMUNOLOGY, vol. 1, no. 6, September 2012 (2012-09-01), pages e25238 - 907
TRENDS IN IMMUNOLOGY, vol. 30, no. 1, August 2013 (2013-08-01), pages 23 - 32
IMMUNITY, vol. 33, 29 October 2010 (2010-10-29), pages 492 - 503
WORLD JOURNAL OF VACCINES, vol. 1, 2011, pages 33 - 78
JOURNAL OF TRANSLATIONAL MEDICINE, vol. 12, 2014, pages 97
N ENGL J MED, vol. 372, 2015, pages 2509 - 2520
SIMON R: "Optimal two-stage designs for phase II clinical trials", CONTROL CLIN. TRIALS., vol. 10, no. 1, 1989, pages 1 - 10, XP023802075, DOI: 10.1016/0197-2456(89)90015-9
See also references of EP 4066852A4
NAKAJIMA, M. ET AL.: "A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 69, March 2020 (2020-03-01), pages 1651 - 1662, XP037187737, DOI: 10.1007/s00262-020-02518-7
MENON S ET AL., CANCERS, vol. 8, 2016, pages 106
PARDOLL DM., NAT REV CANCER, vol. 12, 2012, pages 252 - 264
WOLCHOK JD., CELL, vol. 162, 2015, pages 937
ONCOIMMUNOLOGY, vol. 1, no. 5, August 2012 (2012-08-01), pages 699 - 716
ONCOIMMUNOLOGY, vol. 1, no. 6, September 2012 (2012-09-01), pages e25238 - 907
TRENDS IN IMMUNOLOGY, vol. 30, no. 1, August 2013 (2013-08-01), pages 23 - 32
IMMUNITY, vol. 33, 29 October 2010 (2010-10-29), pages 492 - 503
WORLD JOURNAL OF VACCINES, vol. 1, 2011, pages 33 - 78
JOURNAL OF TRANSLATIONAL MEDICINE, vol. 12, 2014, pages 97
N ENGL J MED, vol. 372, 2015, pages 2509 - 2520
SIMON R: "Optimal two-stage designs for phase II clinical trials", CONTROL CLIN. TRIALS., vol. 10, no. 1, 1989, pages 1 - 10, XP023802075, DOI: 10.1016/0197-2456(89)90015-9
See also references of EP 4066852A4
Attorney, Agent or Firm:
UMEDA Shinsuke (JP)
Download PDF: